AMPE - Ampio posts encouraging results from Ampion COVID-19 pre-clinical study

Ampio Pharmaceuticals ([[AMPE]]) announces results of a pre-clinical study demonstrating that Ampion inhibits an important pro-inflammatory pathway in the types of immune cells implicated in COVID-19 and Lupus Nephritis, a condition that causes inflammation of the kidney.The aim of the study was to evaluate the ability of Ampion to suppress TLR7 signaling and, thereby, reduce the pro-inflammatory chemokine, CXCL10.Ampion reduced pro-inflammatory cytokine release CXCL10 up to 92% compared to a saline solution (p<0.05).This result implies a role for the drug in inhibiting the upregulated TLR7 signaling shown in the devastating kidney complication of systemic lupus erythematous, lupus nephritis.

For further details see:

Ampio posts encouraging results from Ampion COVID-19 pre-clinical study